An increase of liver weight (Figure 1C), and the acquisition of a steatotic phenotype (Figure 1D) were also observed, in association with enhanced expression of inflammatory cytokines (IL-6, TNF-α, IL-1β) and fibrosis markers (Col1a1, Mmp2) (Figure 1E), collectively recapitulating the occurrence of a NAFLD-like clinical phenotype. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.